PE Biosystems DNA Analyzer Demand, Strong Sales Boost Stock 26% In Q3
This article was originally published in The Gray Sheet
Executive Summary
Continued strong demand for the ABI Prism 3700 DNA analyzer, order growth across a broad range of additional products and release of financial results ahead of some analysts' estimates contributed to a 25.9% jump in PE Biosystems' stock price during the third quarter.
You may also be interested in...
Boston Scientific's Rotablator Anticipated To Generate $15 mil. In Q4 Sales
A limited reintroduction of Boston Scientific's original Rotablator rotational atherectomy device later this month is anticipated to generate $15 mil. in sales for the firm in the fourth quarter.
GE Medical Systems To Control U.S. C-Arm Imaging Market Via OEC Purchase
GE Medical Systems will gain a controlling stake of the U.S. mobile C-arm fluoroscopy imaging market through its $480 mil. purchase of OEC Medical Systems, announced Aug. 9.
Boston Scientific Pursues Dual Strategy In Addressing RotaLink Recall
Boston Scientific may opt to restart production of its original Rotablator atherectomy system following the Aug. 6 recall of the next-generation RotaLink Plus, the company reported at a same-day teleconference.